BR-101801 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BR-101801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-101801 is under development for the treatment of relapsed/refractory B-cell lymphomas including mantle cell lymphoma, marginal zone lymphoma, Waldensian's macroglobulinemia, chronic lymphocytic leukemia, peripheral T-cell lymphomas and follicular lymphoma. It acts by targeting DNA activated protein kinase (DNA-PK), phosphatidylinositol 3 kinase delta (PI3Kdelta) and (PI3KGamma). It is administered through oral route. It was under development for the treatment of diffuse large B-cell lymphoma,.
Boryung Pharmaceutical overview
Boryung Pharmaceutical (Boryung)is a pharmaceutical company. It manufactures and distributes pharmaceutical products including cardiovascular, anticancer and gastrointestinal drugs. The company offers products such as kanarb, kanab plus, dukarb, dukaro, akarb, VCS inj, velkin injection, alimxid injection, effcil injection, oxalitin, neoplatin, EP mycin and AD mycin. Boryung gastrointestinal includes gelfosM for the treatment of hypogastric acidity, heartburn, gastric and duodenal ulcer, gastritis, gastralgia and nausea. The company also provides marketed API. Boryung is headquartered in Seoul, South Korea.
For a complete picture of BR-101801’s drug-specific PTSR and LoA scores, buy the report here.